Axxcess Wealth Management LLC Sells 1,626 Shares of AstraZeneca PLC $AZN

Axxcess Wealth Management LLC cut its position in AstraZeneca PLC (NASDAQ:AZN) by 7.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,989 shares of the company’s stock after selling 1,626 shares during the quarter. Axxcess Wealth Management LLC’s holdings in AstraZeneca were worth $1,397,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after acquiring an additional 3,224,251 shares during the last quarter. Valeo Financial Advisors LLC raised its position in shares of AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after acquiring an additional 2,307,047 shares during the last quarter. American Century Companies Inc. raised its position in shares of AstraZeneca by 406.9% during the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock worth $148,517,000 after acquiring an additional 1,621,974 shares during the last quarter. Boston Partners raised its position in shares of AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after acquiring an additional 1,329,166 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of AstraZeneca by 650.1% during the first quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock worth $90,761,000 after acquiring an additional 1,070,223 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Down 0.3%

Shares of AstraZeneca stock opened at $84.83 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $86.57. The stock has a 50 day moving average price of $79.82 and a two-hundred day moving average price of $73.69. The stock has a market capitalization of $263.09 billion, a PE ratio of 31.89, a price-to-earnings-growth ratio of 1.56 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.08 billion. During the same quarter last year, the firm posted $1.24 earnings per share. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a $0.505 dividend. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AZN shares. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Berenberg Bank set a $97.00 target price on AstraZeneca in a research note on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.